Peter Ordentlich has sold SNDX and made no open-market buys since May 2017

Peter Ordentlich, Ph.D. is a co‑founder and Chief Scientific Officer of Syndax Pharmaceuticals Inc. (SNDX), where he has led scientific strategy and drug discovery efforts since co‑founding the company in October 2005.( He has served as Chief Scientific Officer since September 2016, following earlier executive roles including Chief Technical Officer, Vice President of Translational Medicine, Executive Director of Translational Science, and Director of Scientific Affairs and Strategic Alliances, reflecting a career focused on translating cutting‑edge biology into oncology therapeutics.( As a corporate insider, he has been involved in Syndax’s development of small‑molecule and other targeted cancer therapies aimed at extending and improving the lives of patients.(

Before founding Syndax, Ordentlich was a scientist at the Salk Institute for Biological Studies, where he worked on identifying small molecules as potential therapeutics and studied synergistic combinations of histone deacetylase inhibitors and nuclear receptor ligands.( He previously spent five years as a research scientist at X‑Ceptor Therapeutics, Inc., a drug discovery company later acquired by Exelixis, Inc.( Ordentlich earned both his B.A. in Biochemistry and Ph.D. in Immunology from the University of Pennsylvania, providing the scientific foundation for his leadership in translational medicine and oncology drug development.(

Written by Perplexity from public sources.